uniQure N.V.
QUREHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeuniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company carries a $1.69B market cap, placing it firmly in the small-cap category. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.
Market Cap
$1.69B
Beta
0.87
P/E (TTM)
—
P/E (Fwd)
-9.44
EPS (TTM)
$-3.49
EPS (Fwd)
$-2.83
ROE
-228.2%
ROA
-17.0%
Cash
$586.6M
Total Debt
$545.7M
Free CF
-$103.7M
52W Change
78.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $586.6M in cash comfortably exceeding the $545.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$103.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -228.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $106.5M (2022) to $16.1M (2025), a 85% decline worth watching.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence uniQure N.V.'s trajectory.